Guardion Health Sciences, Inc. (GHSI)
USD 3.22
(0.0%)
USD 3.22
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 9.73 Million USD | -21.32% |
| 2022 | 11.84 Million USD | -12.89% |
| 2021 | 13.59 Million USD | 60.96% |
| 2020 | 8.44 Million USD | -11.05% |
| 2019 | 9.49 Million USD | 41.98% |
| 2018 | 6.68 Million USD | 20.64% |
| 2017 | 5.54 Million USD | 47.38% |
| 2016 | 3.76 Million USD | -39.26% |
| 2015 | 6.19 Million USD | 750.43% |
| 2014 | 728.2 Thousand USD | -21.54% |
| 2013 | 928.08 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 1.4 Million USD | -35.55% |
| 2024 Q1 | 2.19 Million USD | 7.99% |
| 2023 Q3 | 2.23 Million USD | -1.27% |
| 2023 FY | 9.31 Million USD | -21.32% |
| 2023 Q1 | 2.79 Million USD | 26.11% |
| 2023 Q2 | 2.26 Million USD | -19.2% |
| 2023 Q4 | 2.03 Million USD | -8.78% |
| 2022 Q2 | 3.11 Million USD | -15.74% |
| 2022 Q1 | 3.69 Million USD | -1.2% |
| 2022 FY | 11.84 Million USD | -12.89% |
| 2022 Q4 | 2.21 Million USD | -21.24% |
| 2022 Q3 | 2.81 Million USD | -9.41% |
| 2021 FY | 13.59 Million USD | 60.96% |
| 2021 Q2 | 2.99 Million USD | 8.14% |
| 2021 Q1 | 2.76 Million USD | 11.83% |
| 2021 Q3 | 4.09 Million USD | 36.59% |
| 2021 Q4 | 3.73 Million USD | -8.66% |
| 2020 Q1 | 2.47 Million USD | -7.8% |
| 2020 Q3 | 2.27 Million USD | 85.7% |
| 2020 Q4 | 2.47 Million USD | 9.0% |
| 2020 FY | 8.44 Million USD | -11.05% |
| 2020 Q2 | 1.22 Million USD | -50.52% |
| 2019 Q2 | 2.97 Million USD | 123.68% |
| 2019 Q3 | 2.5 Million USD | -15.91% |
| 2019 Q4 | 2.68 Million USD | 7.17% |
| 2019 FY | 9.49 Million USD | 41.98% |
| 2019 Q1 | 1.33 Million USD | -10.36% |
| 2018 Q4 | 1.48 Million USD | 13.36% |
| 2018 Q3 | 1.3 Million USD | -9.57% |
| 2018 Q2 | 1.44 Million USD | -40.81% |
| 2018 Q1 | 2.44 Million USD | 3.71% |
| 2018 FY | 6.68 Million USD | 20.64% |
| 2017 FY | 5.54 Million USD | 47.38% |
| 2017 Q4 | 2.35 Million USD | 46.1% |
| 2017 Q3 | 1.61 Million USD | 82.63% |
| 2017 Q2 | 884.02 Thousand USD | 28.89% |
| 2017 Q1 | 685.88 Thousand USD | -39.93% |
| 2016 Q1 | 737.7 Thousand USD | -33.12% |
| 2016 FY | 3.76 Million USD | -39.26% |
| 2016 Q4 | 1.14 Million USD | 30.95% |
| 2016 Q3 | 872 Thousand USD | -13.64% |
| 2016 Q2 | 1 Million USD | 36.87% |
| 2015 FY | 6.19 Million USD | 750.43% |
| 2015 Q3 | 2.33 Million USD | -1.04% |
| 2015 Q2 | 2.35 Million USD | -0.0% |
| 2015 Q1 | 2.35 Million USD | 1149.44% |
| 2015 Q4 | 1.1 Million USD | -52.72% |
| 2014 Q4 | 188.68 Thousand USD | 0.0% |
| 2014 FY | 728.2 Thousand USD | -21.54% |
| 2013 FY | 928.08 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -17.908% |
| Alpha Teknova, Inc. | 45.85 Million USD | 78.781% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 95.035% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | 78.306% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 93.888% |
| Cosmos Health Inc. | 26.18 Million USD | 62.832% |
| Journey Medical Corporation | 54.59 Million USD | 82.176% |
| Embecta Corp. | 528.4 Million USD | 98.158% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 96.421% |
| Dynavax Technologies Corporation | 219.14 Million USD | 95.56% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 98.351% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 97.019% |
| PainReform Ltd. | 9.58 Million USD | -1.532% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | 25.857% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | 25.857% |
| SCYNEXIS, Inc. | 51.84 Million USD | 81.232% |
| Safety Shot Inc | 12.1 Million USD | 19.644% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -217.049% |
| Procaps Group, S.A. | 199.47 Million USD | 95.122% |
| Theratechnologies Inc. | 72.75 Million USD | 86.625% |
| Harrow Health, Inc. | 89.97 Million USD | 89.185% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -3.015% |
| Biofrontera Inc. | 39.95 Million USD | 75.648% |
| DURECT Corporation | 43.71 Million USD | 77.74% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 98.161% |
| Cronos Group Inc. | 96.7 Million USD | 89.938% |
| OptiNose, Inc. | 85.1 Million USD | 88.566% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 95.808% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | 75.147% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 201.776% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 96.902% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | 77.391% |
| Radius Health, Inc. | 265.92 Million USD | 96.341% |
| Universe Pharmaceuticals INC | 13.84 Million USD | 29.7% |
| ProPhase Labs, Inc. | 37.85 Million USD | 74.292% |
| Phibro Animal Health Corporation | 260.29 Million USD | 96.262% |
| Procaps Group S.A. | 187.24 Million USD | 94.803% |
| Alvotech | 285.43 Million USD | 96.591% |
| TherapeuticsMD, Inc. | 9.82 Million USD | 0.958% |
| Viatris Inc. | 5.96 Billion USD | 99.837% |
| Rockwell Medical, Inc. | 15.37 Million USD | 36.706% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 83.739% |
| SIGA Technologies, Inc. | 22.04 Million USD | 55.855% |
| Tilray Brands, Inc. | 251.35 Million USD | 96.129% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 80.157% |
| Shineco, Inc. | 17.94 Million USD | 45.783% |
| PetIQ, Inc. | 192.72 Million USD | 94.951% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -143.811% |
| Incannex Healthcare Limited | 30.05 Million USD | 67.621% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 99.39% |
| Alimera Sciences, Inc. | 62.64 Million USD | 84.466% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -1176.188% |
| Assertio Holdings, Inc. | 368.58 Million USD | 97.36% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -65.334% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | 45.359% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | 54.033% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 53.755% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 94.101% |
| Hempacco Co., Inc. | 7.59 Million USD | -28.097% |
| Talphera, Inc. | 11.99 Million USD | 18.869% |
| Alvotech | 285.43 Million USD | 96.591% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 93.085% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 97.179% |
| Currenc Group, Inc. | 24 Million USD | 59.458% |
| Kamada Ltd. | 45.42 Million USD | 78.579% |
| Indivior PLC | 911 Million USD | 98.932% |
| Evoke Pharma, Inc. | 12.4 Million USD | 21.587% |
| Flora Growth Corp. | 10.57 Million USD | 8.017% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 53.755% |
| Evolus, Inc. | 189.75 Million USD | 94.872% |
| HUTCHMED (China) Limited | 436.23 Million USD | 97.769% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 93.687% |
| Akanda Corp. | 3.48 Million USD | -179.34% |